To report a rare case of metachronous multicentric giant cell tumor of bone (MGCTB) with pulmonary metastases and analyze the long-term management outcomes, highlighting its significance in the context of existing literature.
Key Findings:
MGCTB is extremely rare, comprising less than 1% of GCTB cases, which poses unique management challenges.
Denosumab effectively stabilized disease progression in this patient over a long-term follow-up, suggesting its potential as a standard treatment.
Surgical interventions alone were insufficient to control the disease, highlighting the need for continuous systemic therapy.
Interpretation:
This case illustrates the complexities of managing MGCTB and emphasizes the critical role of targeted biologic therapy in achieving long-term disease control.
Limitations:
The rarity of MGCTB limits the generalizability of findings, necessitating caution in applying results to broader populations.
Long-term effects and optimal duration of denosumab therapy remain uncertain, warranting further investigation.
Conclusion:
Continuous systemic therapy, particularly with denosumab, is essential for managing advanced MGCTB, even amidst surgical challenges.
